id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12856 R48497 |
Thomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Gastro-intestinal malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.10 [0.00;5.15] C excluded (control group) |
0/490 0/50 | 0 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12858 R48509 |
Thomas (Carbamazepine) (Controls unexposed, sick), 2021 | Gastro-intestinal malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.23 [0.01;5.68] C | 0/490 1/340 | 1 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9655 R34369 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Gastrointestinal tract defect | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.79 [0.26;2.42] C | 5/1,657 8/2,098 | 13 | 1,657 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9643 R34308 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Digestive | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 0.91 [0.20;4.09] C | 3/685 4/833 | 7 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 0.76 [0.32;1.80] | 21 | 2,832 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls exposed to Lamotrigine, sick; 3: Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 12856